Skip to content

Zenas BioPharma

US · ZBIO #2856 by market cap Listed 2024
23.85 -1.19 -4.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 24.69 -1.40%
After-hours 23.00 -3.56%
33.7717.1323.852026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ZBIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -28.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -2,113.9% Better than 2%
Net margin -3,777.4% Better than 1%
Return on equity -136.2% Better than 4%
Return on invested capital -137.4% Better than 1%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.1% Better than 22%
6-month return 25.7% Better than 87%
12-month return (ex latest month) -21.1% Better than 14%
Distance below 52-week high 46.5% Better than 22%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.6x Better than 88%
Debt to assets 0.3% Better than 97%
Interest coverage -50.6x Better than 7%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 73.3% Better than 77%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -14.85%
1M -15.37%
3M -24.57%
6M +21.93%
YTD -34.32%
1Y -31.54%

Key statistics

Price & volume

Prev close
25.04
Open
24.75
Day range
23.78 - 25.64
Avg price
24.24
Volume
579.90K
Turnover
14.05M
Amplitude
7.42%
52-week range
13.50 - 44.60

Valuation

P/E
-2.83
P/E (TTM)
-2.37
P/B
7.62
EPS
-8.44
Net profit
-572.38M
Net assets
212.34M

Share structure

Market cap
1.62B
Float cap
950.22M
Shares out
67.82M
Float shares
39.84M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-09-13
52-week range 33% of range
13.50 44.60

46.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-362.55K net over the window

Short interest

Shares short
11.35M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Zenas BioPharma (ZBIO)?

Zenas BioPharma last traded at 23.85. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Zenas BioPharma's market cap?

About 1.62B.

What is the P/E ratio of Zenas BioPharma?

The trailing twelve-month P/E is -2.37. The Valuation tab shows it against the stock's own five-year range.

Does Zenas BioPharma pay a dividend?

Zenas BioPharma does not currently pay a regular dividend.

Is Zenas BioPharma a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 41.33, which implies 73.3% upside from the current price. This is not investment advice.

What is Zenas BioPharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Zenas BioPharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Zenas BioPharma discussion 0 comments

Add a comment